Archives: Agenda

Clinical trials surged in H1 2025! What happened and what you must know to stay ahead

GlobalData’s clinical trials data indicates that new trials initiated in H1 2025 has increased significantly over previous years. In addition to surprising Wall Street, this has shaken up the biopharma competitive landscape and created major opportunities for CROs, CDMOs, Pharma Tech, and consultancies. Behind the headlines, clinical trial reporting lags, shifting start dates, and withdrawals make it easy to miss where the real growth is happening.

This session breaks down what drove the surge, where the next wave is coming from, and how early signals can give you the edge on predicting future market shifts. Whether you run trials, manufacture at scale, or advise life sciences companies, this is about being prepared, before your competitors are.

Interactive Breakfast Speaker-Hosted Roundtable Discussions

With drinks and refreshments, interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Each discussion will run twice and be led by a table moderator and will focus on a different challenge within clinical trials. Roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

Roundtable 1 Navigating the latest release of ICH E6 (R3): How are you carrying out gap assessments of processes and what changes are you making?

Hosted by Christina Sanchez, Director, Clinical Quality Assurance, Neurocrine Biosciences
Roundtable 2 Postproduction handling and administration of biologics drugs 

Hosted by Kevin Zen, Director, Opthea
Roundtable 3 Collaborative solutions between Sponsors and CROs for accurate site budgeting and forecasting

Hosted by Richard Firth, Associate Director, Development Business Operations, Arcturus Therapeutics
Roundtable 4 Emerging startup company trends and challenges
Roundtable 5 Implications of the latest administration on clinical trial progress

CLOSING PANEL DISCUSSION: Ensuring your FSP model is a success

  • Working closely with FSP vendors: how much oversight do you need?
  • Benefits and challenges of moving to an FSP outsourcing model
  • Comparing vendor management strategies between pharma and biotechs: do you need a different approach?
  • Why is FSP becoming a popular outsourcing model: what benefits can this offer sponsors?

Moderator: Amanda Murphy, Senior Director, Data Intelligence & Solutions, GlobalData